Castleman disease: Experience from a single institution

Abraham,Sherry S.; Narayanan,Geetha; Thambi,Sugeeth Mangalapilly; Vasudevan,Jayasudha Arundhathi; Joy Philip,Deepa Susan; Purushothaman,Prakash N.; Nair,Sreejith G.; Nair,Rekha

doi:10.3892/mi.2023.116

Castleman disease: Experience from a single institution

Authors:
- Sherry S. Abraham
- Geetha Narayanan
- Sugeeth Mangalapilly Thambi
- Jayasudha Arundhathi Vasudevan
- Deepa Susan Joy Philip
- Prakash N. Purushothaman
- Sreejith G. Nair
- Rekha Nair
View Affiliations

Affiliations: Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala 695011, India, Department of Pathology, Regional Cancer Centre, Thiruvananthapuram, Kerala 695011, India
Published online on: October 6, 2023 https://doi.org/10.3892/mi.2023.116
Article Number: 56
Copyright : © Abraham et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Castleman disease (CD) describes a group of rare heterogeneous lymphoproliferative disorders characterized by enlarged hyperplastic lymph nodes. It is classified into unicentric CD (UCD) and multicentric CD (MCD). The present retrospective study examined the data of 11 patients with CD diagnosed and treated at a tertiary cancer center from 2017 to 2022. The median age of the study group was 41 years (range, 24 to 68 years). There were 8 males and 3 females. In total, 7 patients were diagnosed with UCD and 4 patients with MCD. The hyaline‑vascular variant was the most common histology in both UCD and MCD. Among the 7 patients with UCD, 5 patients underwent excision, 1 patient underwent debulking followed by radiotherapy and 1 patient received single agent rituximab. Of the patients with UCD, 6 had a complete response (CR) and 1 patient had a partial response (PR). All 4 patients with MCD received systemic treatment, which included single agent rituximab (2 patients), rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (RCHOP) (1 patient) and CHOP (1 patient). Among the patients with MCD, 1 patient attained a CR, 2 patients had a PR and 1 patient succumbed. The 3‑year survival rate for the study population was 91%. In summary, CD is a rare disease occurring in immunodeficient patients. UCD is more common and is associated with better outcomes. Surgery is the mainstay of management in UCD whereas MCD requires combination chemotherapy.

View Figures

View References

1	Jiang JP, Shen XF, Du JF and Guan WX: A retrospective study of 34 patients with unicentric and multicentric Castleman's disease: Experience from a single institution. Oncol Lett. 15:2407–2412. 2018.PubMed/NCBI View Article : Google Scholar
2	Casper C: The aetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care. Br J Haematol. 129:3–17. 2005.PubMed/NCBI View Article : Google Scholar
3	Krause JR, Robinson SD and Vance EA: Multicentric Castleman's disease and HIV. Proc Bayl Univ Med Cent. 27:28–30. 2014.PubMed/NCBI View Article : Google Scholar
4	Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T, Shiota M, Sata T, Higashihara M and Mori S: HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int. 51:671–679. 2001.PubMed/NCBI View Article : Google Scholar
5	Fajgenbaum DC, van Rhee F and Nabel CS: HHV-8-negative, idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis, and therapy. Blood. 123:2924–2933. 2014.PubMed/NCBI View Article : Google Scholar
6	Talat N, Belgaumkar AP and Schulte KM: Surgery in Castleman's disease: A systematic review of 404 published cases. Ann Surg. 255:677–684. 2012.PubMed/NCBI View Article : Google Scholar
7	Keller AR, Hochholzer L and Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 29:670–683. 1972.PubMed/NCBI View Article : Google Scholar
8	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
9	Castleman B, Iverson L and Menendez VP: Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 9:822–830. 1956.PubMed/NCBI View Article : Google Scholar
10	Talat N and Schulte KM: Castleman's disease: Systematic analysis of 416 patients from the literature. Oncologist. 16:1316–1324. 2011.PubMed/NCBI View Article : Google Scholar
11	Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, et al: Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 129:1658–1668. 2017.PubMed/NCBI View Article : Google Scholar
12	Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, Zhu XL, Liu XY and Sun KL: A retrospective study of unicentric and multicentric Castleman's disease: A report of 52 patients. Med Oncol Northwood Lond Engl. 27:1171–1178. 2010.PubMed/NCBI View Article : Google Scholar
13	Liu W, Cai Q, Yu T, Strati P, Hagemeister FB, Zhai Q, Zhang M, Li L, Fang X, Li J, et al: Clinical characteristics and outcomes of Castleman disease: A multicenter Consortium study of 428 patients with 15-year follow-up. Am J Cancer Res. 12:4227–4240. 2022.PubMed/NCBI
14	Dispenzieri A and Fajgenbaum DC: Overview of Castleman disease. Blood. 135:1353–1364. 2020.PubMed/NCBI View Article : Google Scholar
15	van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, et al: International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 4:6039–6050. 2020.PubMed/NCBI View Article : Google Scholar
16	Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A and Habermann TM: The clinical spectrum of Castleman's disease. Am J Hematol. 87:997–1002. 2012.PubMed/NCBI View Article : Google Scholar
17	Neuhof D and Debus J: Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol Stockh Swed. 45:1126–1131. 2006.PubMed/NCBI View Article : Google Scholar
18	Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, et al: Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 147:836–839. 2007.PubMed/NCBI View Article : Google Scholar
19	Pria AD, Pinato D, Roe J, Naresh K, Nelson M and Bower M: Relapse of HHV-8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. Blood. 129:2143–2147. 2017.PubMed/NCBI View Article : Google Scholar
20	Van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, et al: International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 132:2115–2124. 2018.PubMed/NCBI View Article : Google Scholar